Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Five Prime Therapeutics (anti-immunosuppression drug)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

The anti-immune-suppression drug is a a anti body that blocks a tumor. The asset is a antibody drug which blocks a tumor that that blunts an immune response to cancer cells. This drug is created for the treatment of cancer.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Primary Office
  • South San Francisco, CA 94080
  • United States

Five Prime Therapeutics (anti-immunosuppression drug) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Five Prime Therapeutics (anti-immunosuppression drug)‘s full profile, request access.

Request full access to PitchBook

Five Prime Therapeutics (anti-immunosuppression drug) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Five Prime Therapeutics (anti-immunosuppression drug)‘s full profile, request access.

Request full access to PitchBook